Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Ionis Pharmaceuticals, Inc. or Alvotech because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Ionis Pharmaceuticals, Inc. and Alvotech compare based on key financial metrics to determine which better meets your investment needs.

About Ionis Pharmaceuticals, Inc. and Alvotech

Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy. It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 which is in Phase 3 clinical trial for the potential treatment of AS, a rare genetic neurological disease. In addition, the company develops Eplontersen to degrade mutant and wild-type TTR mRNA through binding to the TTR mRNA; Pelacarsen to inhibit the production of apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus; Sefaxersen to reduce the production of complement factor B and lower activation of the alternative complement pathway; and Ulefnersen to reduce the production of the fused in sarcoma, as well as other mid-stage pipeline investigational medicines. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi. The company was incorporated in 1989 and is headquartered in Carlsbad, California.

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, ankylosing spondylitis ulcerative colitis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product for the treatment of adult patients with moderate to severe ulcerative colitis and moderate to severely active Crohn’s disease; AVT23, a biosimilar to Xolair to treat allergic asthma, chronic spontaneous urticaria (CSU), and nasal polyp; and AVT33, a biosimilar to Keytruda product which is in early phase development. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

Latest Biotechnology and Ionis Pharmaceuticals, Inc., Alvotech Stock News

As of July 14, 2026, Ionis Pharmaceuticals, Inc. had a $9.1 billion market capitalization, compared to the Biotechnology median of $277.1 million. Ionis Pharmaceuticals, Inc.’s stock is NA in 2026, NA in the previous five trading days and up 31.63% in the past year.

Currently, Ionis Pharmaceuticals, Inc. does not have a price-earnings ratio. Ionis Pharmaceuticals, Inc.’s trailing 12-month revenue is $1.1 billion with a -30.9% net profit margin. Year-over-year quarterly sales growth most recently was 87.0%. Analysts expect adjusted earnings to reach $-2.614 per share for the current fiscal year. Ionis Pharmaceuticals, Inc. does not currently pay a dividend.

Currently, Alvotech does not have a price-earnings ratio. Alvotech’s trailing 12-month revenue is $562.0 million with a -14.4% net profit margin. Year-over-year quarterly sales growth most recently was -30.9%. Analysts expect adjusted earnings to reach $0.027 per share for the current fiscal year. Alvotech does not currently pay a dividend.

How We Compare Ionis Pharmaceuticals, Inc. and Alvotech Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Ionis Pharmaceuticals, Inc. and Alvotech’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Ionis Pharmaceuticals, Inc. and Alvotech Stock Value Grades

Company	Ticker	Value
Ionis Pharmaceuticals, Inc.	IONS	F
Alvotech	ALVO	D

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Ionis Pharmaceuticals, Inc. has a Value Score of 6, which is Ultra Expensive. Alvotech has a Value Score of 29, which is Expensive.

The Value Stock Winner: No Clear Winner

Neither Ionis Pharmaceuticals, Inc. or Alvotech has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if Ionis Pharmaceuticals, Inc. or Alvotech is the better investment when it comes to value.

Ionis Pharmaceuticals, Inc. and Alvotech Growth Grades

Company	Ticker	Growth
Ionis Pharmaceuticals, Inc.	IONS	F
Alvotech	ALVO	F

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Ionis Pharmaceuticals, Inc. has a Growth Score of 19, which is Very Weak. Alvotech has a Growth Score of 18, which is Very Weak.

The Growth Stock Winner: No Clear Winner

Neither Ionis Pharmaceuticals, Inc. or Alvotech has a high enough Growth Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Ionis Pharmaceuticals, Inc. or Alvotech is the better investment when it comes to sustainable growth.

Ionis Pharmaceuticals, Inc. and Alvotech’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Ionis Pharmaceuticals, Inc.	IONS	C
Alvotech	ALVO	B

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Ionis Pharmaceuticals, Inc. has a Earnings Estimate Score of 57, which is Neutral. Alvotech has a Earnings Estimate Score of 78, which is Positive.

The Earnings Estimate Revisions Grade Winner: Alvotech

As you can clearly see from the Earnings Estimate Revisions Grade breakdown above, Alvotech has a better Earnings Estimate Revisions Grade than Ionis Pharmaceuticals, Inc.. For those who are specifically looking for companies with better short-term prospects when compared to other companies in the same industry, Alvotech could be a good stock to invest in. However, it’s important to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Ionis Pharmaceuticals, Inc. and Alvotech Grades

In addition to Growth, Value and Estimate Revisions, A+ Investor also provides grades for Momentum and Quality.

Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Ionis Pharmaceuticals, Inc. and Alvotech pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Ionis Pharmaceuticals, Inc. or Alvotech Stock?

Overall, Ionis Pharmaceuticals, Inc. stock has a Value Score of 6, Growth Score of 19 and Estimate Revisions Score of 57.

Alvotech stock has a Value Score of 29, Growth Score of 18 and Estimate Revisions Score of 78.

Comparing Ionis Pharmaceuticals, Inc. and Alvotech’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.